The estimated Net Worth of Keith Wayne Ward is at least $8.34 Million dollars as of 25 February 2019. Keith Ward owns over 40,367 units of Reata Pharmaceuticals Inc stock worth over $1,485,743 and over the last 9 years Keith sold RETA stock worth over $6,852,651.
Keith has made over 8 trades of the Reata Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Keith sold 40,367 units of RETA stock worth $3,678,645 on 25 February 2019.
The largest trade Keith's ever made was selling 40,367 units of Reata Pharmaceuticals Inc stock on 25 February 2019 worth over $3,678,645. On average, Keith trades about 7,548 units every 19 days since 2016. As of 25 February 2019 Keith still owns at least 8,620 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Keith Ward stock trades at the bottom of the page.
Keith's mailing address filed with the SEC is 2801 Gateway Dr #150, Irving, TX 75063, USA.
Over the last 9 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy und Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: